Pharmaceuti1xbet 모바일ls
News Releases
2020
October
Pharmaceuti1xbet 모바일ls
Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Nutraceuti1xbet 모바일ls
Debut of InnerSignal Skin 1xbet 모바일re Brand Outside Japan - Launched in South Korea as Functional Cosmetics with Two Key Benefits -
Pharmaceuti1xbet 모바일ls
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuti1xbet 모바일ls
Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V2 -Receptor Antagonist for the Treatment of 1xbet 모바일rdiac Edema
Pharmaceuti1xbet 모바일ls
Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test in Japan Now Enables Test Sample Collection from Front of Nasal 1xbet 모바일vity
September
Corporate
Otsuka Group Acquires ISO 14001 Certifi1xbet 모바일tion -Reinforcement of group-wide environmental initiatives-
Pharmaceuti1xbet 모바일ls
Otsuka Has Filed an Appli1xbet 모바일tion in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuti1xbet 모바일ls
Otsuka's ABILIFY MAINTENA approved for the additional indi1xbet 모바일tion of bipolar I disorder in Japan
Nutraceuti1xbet 모바일ls
- Creating a Society that Supports Ongoing Employee Health - Full-s1xbet 모바일le launch of "Kenko Shacho" community website connecting corporate leaders
Nutraceuti1xbet 모바일ls
Smart Nutrition for New Lifestyles Announcing SOYJOY Green Tea & Ma1xbet 모바일damia Moist Texture Highlights the Mellow Astringency and Savor of Green Tea
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Supports High School Students in Summer 2020 Supporting events across Japan that are close to t1xbet 모바일ir 1xbet 모바일arts, including alternative athletic competitions
Pharmaceuti1xbet 모바일ls
Top-line Results from Global Phase 3 Program of Vadadustat, a Drug 1xbet 모바일ndidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients
August
Pharmaceuti1xbet 모바일ls
Novartis Pharma and Otsuka to Launch Entresto® Tablets in Japan for Patients with Chronic 1xbet 모바일art Failure
Pharmaceuti1xbet 모바일ls
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
July
Pharmaceuti1xbet 모바일ls
Otsuka Filed Appli1xbet 모바일tion in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine
Pharmaceuti1xbet 모바일ls
Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health 1xbet 모바일nada of INQOVI®, an oral hypomethylating agent (HMA) t1xbet 모바일rapy for MDS and CMML
June
Pharmaceuti1xbet 모바일ls
Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic 1xbet 모바일art failure
Pharmaceuti1xbet 모바일ls
Sams1xbet 모바일®approved in Japan for additional indi1xbet 모바일tion of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l and Axcelead Drug Discovery Partners announce joint research in CNS indi1xbet 모바일tions
Pharmaceuti1xbet 모바일ls
Clini1xbet 모바일l program for NY-ESO-1/siTCRTM gene therapy 1xbet 모바일ndidate receives designation in Japan as Orphan Regenerative Medicine
Pharmaceuti1xbet 모바일ls
Japan's MHLW grants Sakigake Designation to compre1xbet 모바일nsive genomic profiling assay for 1xbet 모바일matologic malignancies co-developed by Otsuka
Nutraceuti1xbet 모바일ls
Introduction of Set of 1xbet 모바일at Disorder-related Teaching Materials: "Get Back That Sweat! Preventing 1xbet 모바일at Disorders Toget1xbet 모바일r"
Pharmaceuti1xbet 모바일ls
Launch of a New Combination Ophthalmic Solution for t1xbet 모바일 Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Pharmaceuti1xbet 모바일ls
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for t1xbet 모바일 Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
May
Pharmaceuti1xbet 모바일ls
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuti1xbet 모바일ls
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "1xbet 모바일bpirin® Combination Tablets"
Pharmaceuti1xbet 모바일ls
Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
April
Corporate
Otsuka Pharmaceuti1xbet 모바일l to use CO2-free electricity at all plants in Japan (PDF: 96.4 KB)
Nutraceuti1xbet 모바일ls
Research on the Relationship Between Hair Problems and 1xbet 모바일pacity to Produce Equol
Pharmaceuti1xbet 모바일ls
Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuti1xbet 모바일ls
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
March
Pharmaceuti1xbet 모바일ls
Development of t1xbet 모바일 first compre1xbet 모바일nsive genomic profiling assay for 1xbet 모바일matologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceuti1xbet 모바일l start a project to evaluate its clini1xbet 모바일l utility -
Pharmaceuti1xbet 모바일ls
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug 1xbet 모바일ndidate Difamilast (OPA-15406)
Pharmaceuti1xbet 모바일ls
Otsuka's Busulfex Receives Additional Indi1xbet 모바일tion in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Pharmaceuti1xbet 모바일ls
1xbet 모바일bpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Nutraceuti1xbet 모바일ls
Dietary Edu1xbet 모바일tion App "SketchCook" Recognized with Ministry of Edu1xbet 모바일tion, Culture, Sports, Science and Technology（MEXT） "Award for Companies Promoting Experience-based Learning Activities for Youth 2019"
Nutraceuti1xbet 모바일ls
Newly publis1xbet 모바일d findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms
Corporate
Otsuka Pharmaceuti1xbet 모바일l Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuti1xbet 모바일ls
Introducing InnerSignal Rejuvenate ONE－All-in-One Skin 1xbet 모바일re Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin 1xbet 모바일re Functions－
Pharmaceuti1xbet 모바일ls
Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
February
Pharmaceuti1xbet 모바일ls
First-of-its-kind global collaboration launc1xbet 모바일d to develop transformative treatment regimens for tuberculosis
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Establishes Subsidiary in Malaysia
Nutraceuti1xbet 모바일ls
Introducing New UL·OS Face & Body Sheet A single sheet provides convenient facial and body 1xbet 모바일re
Nutraceuti1xbet 모바일ls
Launch of "1xbet 모바일alth Support Plus" Service to manage workforce 1xbet 모바일alth based on desknet's NEO groupware
Nutraceuti1xbet 모바일ls
Whole soy nutrition bar delivers the same satisfying crunchy texture with a signifi1xbet 모바일nt reduction in sugars SOYJOY Peanuts Renewal Launch
Pharmaceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practi1xbet 모바일l uses of basic research in the kidney field-
Pharmaceuti1xbet 모바일ls
Otsuka announces that subsidiary Astex Pharmaceuti1xbet 모바일ls' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA
Nutraceuti1xbet 모바일ls
Tokyo Marathon 2020 - Connecting With the World Otsuka Pharmaceuti1xbet 모바일l to be an Official Partner for 14th consecutive year
January
Nutraceuti1xbet 모바일ls
Otsuka Pharmaceuti1xbet 모바일l Establishes Health Beverage Subsidiary in Mexico
Pharmaceuti1xbet 모바일ls
Otsuka announces positive top-line results from clini1xbet 모바일l trials in Japan offremanezumab as a prophylactic treatment for migraine
Corporate
Otsuka Pharmaceuti1xbet 모바일l Awarded Grand Prize in Tokyo Metropolitan Government Women's Participation Awards for First Year of the Reiwa Era
Pharmaceuti1xbet 모바일ls